BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

489 related articles for article (PubMed ID: 15521794)

  • 1. Amisulpride: a review of its use in the management of schizophrenia.
    McKeage K; Plosker GL
    CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amisulpride: a review of its use in the management of schizophrenia.
    Curran MP; Perry CM
    Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spotlight on amisulpride in schizophrenia.
    Curran MP; Perry CM
    CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Olanzapine: an updated review of its use in the management of schizophrenia.
    Bhana N; Foster RH; Olney R; Plosker GL
    Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
    Swainston Harrison T; Perry CM
    Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Which role for amisulpride in rehabilitation of schizophrenic patients with acute exacerbation?
    Blin O
    Encephale; 2000 Oct; 26 Spec No 1():7-11. PubMed ID: 11294060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
    Leucht S
    Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical issues with amisulpride in the management of patients with schizophrenia.
    Pani L; Villagrán JM; Kontaxakis VP; Alptekin K
    Clin Drug Investig; 2008; 28(8):465-77. PubMed ID: 18598092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amisulpride: progress and outcomes.
    Lecrubier Y
    Curr Med Res Opin; 2002; 18 Suppl 3():s18-22. PubMed ID: 12418608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of negative symptoms in schizophrenia by amisulpride. Review of the literature].
    Pélissolo A; Krebs MO; Olié JP
    Encephale; 1996; 22(3):215-9. PubMed ID: 8767050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amisulpride compared with standard neuroleptics in acute exacerbations of schizophrenia: three efficacy studies.
    Freeman HL
    Int Clin Psychopharmacol; 1997 May; 12 Suppl 2():S11-7. PubMed ID: 9218163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amisulpride: a review of its efficacy in schizophrenia.
    Möller HJ
    Acta Psychiatr Scand Suppl; 2000; 400():17-22. PubMed ID: 10823307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroendocrine responsivities of the pituitary dopamine system in male schizophrenic patients during treatment with clozapine, olanzapine, risperidone, sulpiride, or haloperidol.
    Markianos M; Hatzimanolis J; Lykouras L
    Eur Arch Psychiatry Clin Neurosci; 2001 Jun; 251(3):141-6. PubMed ID: 11697576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical advantages of amisulpride in the treatment of acute schizophrenia.
    Burns T; Bale R
    J Int Med Res; 2001; 29(6):451-66. PubMed ID: 11803729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride.
    Nuss P; Tessier C
    Curr Med Res Opin; 2010 Apr; 26(4):787-801. PubMed ID: 20121655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group.
    Danion JM; Rein W; Fleurot O
    Am J Psychiatry; 1999 Apr; 156(4):610-6. PubMed ID: 10200742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity.
    Schoemaker H; Claustre Y; Fage D; Rouquier L; Chergui K; Curet O; Oblin A; Gonon F; Carter C; Benavides J; Scatton B
    J Pharmacol Exp Ther; 1997 Jan; 280(1):83-97. PubMed ID: 8996185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
    Leucht S; Pitschel-Walz G; Engel RR; Kissling W
    Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.